ONWARD Medical schedules 2025 full-year financial results — ARC-EX non-invasive SCS advances in SCI
Summary
ONWARD Medical, the Swiss-Dutch company developing both non-invasive and implantable spinal cord stimulation for spinal cord injury, scheduled its full-year 2025 financial results webcast as the company advances ARC-EX — its CE-marked transcutaneous spinal cord stimulation system — toward broader European and US commercial adoption. ARC-EX received FDA Breakthrough Device designation and builds on the landmark EPFL/CHUV Nature Medicine publications showing walking restoration in chronic SCI.
Why it matters
ONWARD is the rare neurotech company with both a non-invasive CE-marked product generating revenue and an implantable version in development — a product ladder strategy that allows revenue generation while the higher-value implantable system develops. Their EPFL science pedigree is the strongest in the SCI stimulation space.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial